Health
Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent systemic mastocytosis (ISM). Key presentations include four-year PIONEER clinical study results highlighting sustained symptom control and quality of life improvement in AYVAKIT-treated patients, and real-world data showing meaningful symptom benefit in patients receiving the therapy in a community practi
About this update from Sanofi Sa
[{"type":"text","content":"-- Real-world study of AYVAKIT highlights improvement across ISM symptoms --","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"-- 12 data presentations at 2026 AAAAI Annual Meeting reflect company's leadership in elevating SM care --","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 28, 2026 /PRNewswire/ -- Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent systemic mastocytosis (ISM). Key presentations include four-year PIONEER clinical study results highlighting sustained symptom control and quality of life improvement in AYVAKIT-treated patients, and real-world data showing meaningful symptom benefit in patients receiving the therapy in a community practice setting. In addition, a study conducted with the Advanced Practitioner Society for Hematology and Oncology (APSHO) and The Mast Cell Disease Society (TMS) reinforces the severe symptoms and impaired quality of life experienced by patients with ISM. In total, 12 data presentations are being reported at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, February 27 – March 2 in Philadelphia.","length":981,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Blueprint Medicines)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Blueprint Medicines)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":186,"url":"https://media.zenfs.com/en/prnewswire.com/66d4d034940e0c5a6f4ac4ba630a14a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NpuYza_grizjsylUDnkf_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/66d4d034940e0c5a6f4ac4ba630a14a8","width":400,"height":186}},"href":"https://mma.prnewswire.com/media/2700885/Blueprint_Medicines_a_Sanofi_company_Logo_v2.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Patients with indolent systemic mastocytosis and healthcare providers have expressed the need for a therapy that meaningfully improves quality of life through durable symptom benefit and a safety profile enabling long-term treatment, and AYVAKIT is delivering this significant impact to a wide range of people living with the...